Feb 14 |
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
|
Jan 9 |
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
|
Jan 4 |
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
|
Dec 7 |
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
|
Nov 9 |
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
|
Nov 9 |
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
|
Nov 5 |
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript
|
Nov 3 |
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
|
Nov 3 |
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
|